Page last updated: 2024-11-06

bes

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Occurs in Manufacturing Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

2-[bis(2-hydroxyethyl)amino]ethanesulfonic acid : A Good's buffer substance, pKa = 7.15 at 20 degreeC. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID73243
CHEBI ID39041
SCHEMBL ID99322
MeSH IDM0059105

Synonyms (56)

Synonym
taurine, n,n-bis(2-hydroxyethyl)-
ethanesulfonic acid, 2-(bis(2-hydroxyethyl)amino)-
bes (buffering agent)
2-(bis(2-hydroxyethyl)amino)ethane sulfonic acid
2-(bis(2-hydroxyethyl)amino)ethanesulfonic acid
einecs 233-465-5
brn 1781572
nsc 166667
ai3-62516
2-[bis(2-hydroxyethyl)amino]ethanesulfonic acid
ethanesulfonic acid, 2-[bis(2-hydroxyethyl)amino]-
nsc-166667
10191-18-1
taurine,n-bis(2-hydroxyethyl)-
n,n-bis(2-hydroxyethyl)-2-aminoethanesulfonic acid ,
nsc166667
BES ,
n,n-bis(hydroxyethyl)-2-aminoethanesulfonic acid
hts code 2922.19.9590
bes, bioperformance certified, cell culture tested, >=99.0%
bes, >=99.0% (titration)
bes, bioxtra, >=99.0% (titration)
n,n-bis(2-hydroxyethyl)taurine
CHEBI:39041
2-(bis(2-hydroxyethyl)amino)ethanesulphonic acid
n,n-bis(2-hydroxyethyl)aminoethanesulfonic acid
bes, bioxtra, for molecular biology, >=99.5% (t)
B0909
n,n-bis-(2-hydroxyethyl)-2-aminoethanesulfonic acid
A844612
n,n-bis(2-hydroxyethyl)-2-aminoethanesulphonic acid
FT-0629412
AKOS015896284
BP-20294
SCHEMBL99322
n,n-bis [2-hydroxyethyl]-2-aminoethanesulfonic acid
n,n-di[(2-hydroxy)ethyl]taurine
n,n-bis[2-hydroxyethyl]-2-aminoethanesulfonic acid
DTXSID8064985
n,n-bis(2-hydroxyethyl)-2-aminoethanesulphonic acid;bes
W-108896
AC-27731
mfcd00007533
2-[bis(2-hydroxyethyl)amino]ethane-1-sulfonic acid
bes, >=99.0% (t)
AS-68363
2-[n,n-bis(2-hydroxyethyl)amino]ethanesulfonic acid (bes)
bes, vetec(tm) reagent grade, >=99%
2-[n,n-bis(2-hydroxyethyl)amino]ethanesulfonic acid
SY011179
F20335
bes, free acid
SB78925
A851430
CS-0015176
HY-D0867

Research Excerpts

Effects

BES has the highest Belostoma DNA content, while BSA has the lowest. BES-LSSVM has higher prediction accuracy than the existing particle swarm optimization-least-squares support vector machine.

ExcerptReferenceRelevance
"BES has the highest Belostoma DNA content, while BSA has the lowest."( Chromosomal distribution of major rDNA and genome size variation in Belostoma angustum Lauck, B. nessimiani Ribeiro & Alecrim, and B. sanctulum Montandon (Insecta, Heteroptera, Belostomatidae).
da Rosa, R; Del Valle Garnero, A; Delgado Cañedo, A; Dionísio, JF; Furlan Lopes, C; Gunski, RJ; Inacio Ribeiro, JR; Lemos Costa, A, 2022
)
1.44
"BES-LSSVM has higher prediction accuracy than the existing particle swarm optimization-least-squares support vector machine (PSO-LSSVM), grasshopper optimization algorithm-least-squares support vector machine (GOA-LSSVM), differential evolution-least-squares support vector machine (DE-LSSVM), sparrow search algorithm-least-squares support vector machine (SSA-LSSVM), bald eagle search-back propagation neural network (BES-BPNN), and bald eagle search-extreme learning machine (BES-ELM)."( Survival Risk Prediction of Esophageal Squamous Cell Carcinoma Based on BES-LSSVM.
Song, X; Sun, J; Wang, L; Wang, Y; Zhang, W; Zhao, X, 2022
)
1.68

Toxicity

ExcerptReferenceRelevance
" This supports the use of plant-based essential oil (EO) formulations as they are safe to use with limited effect on non-target organisms."( Ultrasound-assisted nanoemulsion of Trachyspermum ammi essential oil and its constituent thymol on toxicity and biochemical aspect of Aedes aegypti.
Bakthavatsalam, N; Das, T; Eswaramoorthy, M; Govindarajan, R; Manjunath, S; Mohan, MG; Pragadheesh, VS; Samuel, PP; Senthamarai Selvan, P; Senthil-Nathan, S; Senthoorraja, R; Subaharan, K; Subramanya, TM; Uragayala, S, 2022
)
0.72
" Adverse events were recorded throughout the study."( Simoctocog alfa (Nuwiq®) in previously untreated patients with severe haemophilia A-Final efficacy and safety results from the NuProtect study.
Abraham, A; Belletrutti, MJ; Belyanskaya, L; Carcao, M; Carvalho, M; Chambost, H; Chan, AKC; Dubey, L; Ducore, J; Gattens, M; Gresele, P; Gruel, Y; Guillet, B; Jansen, M; Jiménez-Yuste, V; Kitanovski, L; Klukowska, A; Knaub, S; Lohade, S; Mancuso, ME; Mathias, M; Neufeld, EJ; Oldenburg, J; Pollio, B; Sigaud, M; Vilchevska, K; Walter, O; Wu, JKM, 2023
)
0.91
"BES holds promise as a treatment option with low rate of adverse effects for a specific subset of pediatric patients with airway malacia or vascular compression."( Single-center review on safety of biodegradable airway stenting in pediatric population.
Diamantopoulos, A; Durward, A; James, P; Jogeesvaran, H; Minen, F; Morgan, GJ; Nyman, A, 2023
)
2.35

Pharmacokinetics

The pharmacokinetic data were best described by a 2-compartment model, Erlang distribution to describe the absorption phase, and a proportional error. The aim of the present study was to develop population pharmacokinetics (popPK) models and maximum a posteriori Bayesian estimators.

ExcerptReferenceRelevance
" The aim of the present study was to develop population pharmacokinetic (popPK) models and maximum a posteriori Bayesian estimators (MAP-BEs) to estimate mycophenolic acid interdose area under the curve in AIH patients administered MMF using nonlinear mixed effect modelling."( Population pharmacokinetics and Bayesian estimation of mycophenolate mofetil in patients with autoimmune hepatitis.
Marquet, P; Nanga, TM; Prémaud, A; Rousseau, A; Woillard, JB, 2022
)
0.92
"The pharmacokinetic data were best described by a 2-compartment model, Erlang distribution to describe the absorption phase, and a proportional error."( Population pharmacokinetics and Bayesian estimation of mycophenolate mofetil in patients with autoimmune hepatitis.
Marquet, P; Nanga, TM; Prémaud, A; Rousseau, A; Woillard, JB, 2022
)
1.01

Compound-Compound Interactions

ExcerptReferenceRelevance
"This study aimed to investigate the efficacy of Traditional Chinese Herbs (TCH) combined with bioelectrical stimulation (BES) on patients with kidney deficiency and blood stasis type thin endometrium."( Efficacy of Traditional Chinese Herbs combined with bioelectrical stimulation on patients with kidney deficiency and blood stasis type thin endometrium: a retrospective observational study.
Chen, SS; Fan, HY; Huang, LY; Li, XQ, 2023
)
1.12
"TCH combined with EBS has a satisfactory efficacy on patients with kidney deficiency and blood stasis type thin endometrium, and improves EMT, E2 and P levels, reduces PI, RI and TCM syndrome, and eventually leads to a favorable clinical pregnancy outcome."( Efficacy of Traditional Chinese Herbs combined with bioelectrical stimulation on patients with kidney deficiency and blood stasis type thin endometrium: a retrospective observational study.
Chen, SS; Fan, HY; Huang, LY; Li, XQ, 2023
)
0.91

Bioavailability

ExcerptReferenceRelevance
" The mean (relative standard error) of popPK parameter estimates of clearance, intercompartmental clearance, central volume and absorption rate with the final model were: 21."( Population pharmacokinetics and Bayesian estimation of mycophenolate mofetil in patients with autoimmune hepatitis.
Marquet, P; Nanga, TM; Prémaud, A; Rousseau, A; Woillard, JB, 2022
)
0.72

Dosage Studied

ExcerptRelevanceReference
"This post-hoc analysis compared HFC pharmacokinetics (PK) and dosing between patient age groups and defined the in vivo recovery (IVR) for children with a- and hypofibrinogenaemia."( Analysis of fibrinogen concentrate pharmacokinetics and dosing for bleeds and surgery in adults, adolescents, and children with congenital afibrinogenaemia and hypofibrinogenaemia.
Djambas Khayat, C; Knaub, S; Kruzhkova, I; Lohade, SD; Peyvandi, F; Solomon, C; Zekavat, OR, 2022
)
0.72
" Adherence to therapy was assessed by the maximum dosage (MD) and treatment duration (TD)."( Liraglutide 3.0 mg and mental health: can psychiatric symptoms be associated to adherence to therapy? Insights from a clinical audit.
Atti, AR; Nuccitelli, C; Perazza, F; Petroni, ML; Pironi, L; Stecchi, M; Tempia Valenta, S; Villanova, N, 2023
)
0.91
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Occurs in Manufacturing (3 Items)

ItemProcessFrequency
Insektencore-ingredient1
Fleischcore-ingredient1
Auf Fleisch basierende Lebensmittelcore-ingredient1

Drug Classes (3)

ClassDescription
BES
amino sulfonic acidAn organosulfonic acid containing one or more amino groups.
BES
1,1-diunsubstituted alkanesulfonateAn alkanesulfonate in which the carbon at position 1 is attached to at least two hydrogens.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Research

Studies (98)

TimeframeStudies, This Drug (%)All Drugs %
pre-19905 (5.10)18.7374
1990's2 (2.04)18.2507
2000's4 (4.08)29.6817
2010's5 (5.10)24.3611
2020's82 (83.67)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 104.78

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index104.78 (24.57)
Research Supply Index4.69 (2.92)
Research Growth Index6.40 (4.65)
Search Engine Demand Index184.76 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (104.78)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials6 (5.88%)5.53%
Reviews11 (10.78%)6.00%
Case Studies1 (0.98%)4.05%
Observational2 (1.96%)0.25%
Other82 (80.39%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]